Table 1 The relationship between miR-124 expression and clinicopathological parameters in 178 NPC patients
From: MiR-124 suppresses tumor growth and metastasis by targeting Foxq1 in nasopharyngeal carcinoma
Variable | No. | Median expression of miR-124 | P | |
|---|---|---|---|---|
High expression | Low expression | |||
Age, year | Â | Â | Â | 0.188 |
<45 | 95 | 46 (48.4%) | 49 (51.6%) | Â |
≥45 | 83 | 43 (51.8%) | 40 (49.2%) |  |
Gender | Â | Â | Â | 0.749 |
Male | 120 | 57 (47.5%) | 63 (52.5%) | Â |
Female | 58 | 32 (55.1%) | 26 (44.9%) | Â |
T status | Â | Â | Â | <0.001 |
T1 | 34 | 34 (100%) | 0 (0%) | Â |
T2 | 42 | 33 (78.6%) | 9 (21.4%) | Â |
T3 | 58 | 18 (31%) | 40 (69%) | Â |
T4 | 44 | 6 (13.6%) | 38 (86.4%) | Â |
N status | Â | Â | Â | 0.148 |
N0 | 16 | 10 (62.5%) | 6 (37.5%) | Â |
N1 | 80 | 44 (55%) | 36 (45%) | Â |
N2 | 60 | 27 (45%) | 33 (55.0%) | Â |
N3 | 22 | 8 (36.4%) | 14 (63.6%) | Â |
M status | Â | Â | Â | 0.114 |
M0 | 166 | 82 (50%) | 84 (50%) | Â |
M1 | 12 | 7 (58.0%) | 5 (42.0%) | Â |
Stage | Â | Â | Â | Â |
I | 5 | 5 (100%) | 0 (0%) | <0.001 |
II | 37 | 33 (89.1%) | 4 (10.8%) | Â |
III | 70 | 35 (50%) | 35 (50%) | Â |
IV | 60 | 16 (26.7%) | 44 (73.3%) | Â |